文献速递神经肿瘤

靶向PDGFRα激活型胶质母细胞瘤:特异性抑制SHP-2介导的信号传导

Targeting PDGFRα-activated glioblastoma through specific inhibition of SHP-2-mediated signaling.
PubMed 文献 · Neuro Oncol · 2019-01-01

该研究评估了口服SHP-2抑制剂SHP099对PDGFRα信号激活的胶质母细胞瘤(GBM)的疗效。体外和体内实验显示SHP099通过抑制SHP-2刺激的ERK1/2激活及JUN表达,特异性抑制GBM细胞增殖,并在脑内达到有效浓度抑制原位移植瘤生长。SHP099单药或联合替莫唑胺(TMZ)均显示抗肿瘤活性并延长生存期。

要点

  • SHP099选择性抑制PDGFRα激活的GBM细胞和胶质瘤干细胞样细胞存活
  • SHP099在脑内蓄积至有效浓度并抑制原位GBM移植瘤生长
  • SHP099单药或联合TMZ均延长GBM移植瘤动物生存期

核心结论

  • SHP099作为潜在治疗选择,与TMZ联合可能改善GBM临床治疗。

研究设计与样本

  • 研究评估SHP099对神经祖细胞、GBM细胞系和患者来源胶质瘤干细胞样细胞的存活影响,并采用转化小鼠星形胶质细胞和GSC原位异种移植模型评估单药或联合TMZ的疗效。

主要发现

  • SHP099显著抑制已建立GBM细胞、GSC和转化小鼠星形胶质细胞中激活的PDGFRα信号,而神经祖细胞不受影响。
  • SHP099通过靶向SHP-2刺激的ERK1/2激活,特异性抑制PDGFR信号下游效应分子JUN表达,从而减弱PDGFRα激活GBM细胞的细胞周期进展。
  • SHP099在脑内蓄积至有效浓度,有效抑制原位GBM肿瘤异种移植生长。
  • SHP099单药或联合TMZ均显示抗肿瘤活性,并为GBM肿瘤异种移植动物提供显著生存获益。

临床怎么用

  • SHP099可作为PDGFRα激活型GBM的潜在靶向治疗药物,与TMZ联合可能改善治疗效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glioblastoma (GBM) is the most malignant primary brain tumor, with dismal median survival. Treatment of GBM is particularly challenging given the intrinsic resistance to chemotherapy and difficulty of drugs to reach the tumor beds due to the blood-brain barrier. Here, we examined the efficacy of SHP099, a potent, selective, and oral SHP-2 inhibitor for treating GBM with activated platelet derived growth factor receptor alpha (PDGFRα) signaling. METHODS: The effects of SHP099 on cell survival of neural progenitor cells (NPCs), GBM cell lines, and patient-derived glioma stem-like cells (GSCs) were evaluated. Brain and plasma pharmacokinetics of SHP099 and its ability to inhibit SHP-2 signaling were assessed. SHP099 efficacy as a single agent or in combination with temozolomide (TMZ) was assessed using transformed mouse astrocyte and GSC orthotopic xenograft models. RESULTS: Activated PDGFRα signaling in established GBM cells, GSCs, and transformed mouse astrocytes was significantly inhibited by SHP099 compared with NPCs in vitro and in vivo through targeting SHP-2-stimulated activation of extracellular signal-regulated protein kinases 1 and 2 in GBM. SHP099 treatment specifically inhibited expression of JUN, a downstream effector of PDGFR signaling, thereby attenuating cell cycle progression in GBM cells with activated PDGFRα. Moreover, SHP099 accumulated at efficacious concentrations in the brain and effectively inhibited orthotopic GBM tumor xenograft growth. SHP099 exhibited antitumor activity either as a single agent or in combination with TMZ and provided significant survival benefits for GBM tumor xenograft-bearing animals. CONCLUSIONS: Our data demonstrate the utility and feasibility of SHP099 as a potential therapeutic option for improving the clinical treatment of GBM in combination with TMZ.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Sang Y, Hou Y, Cheng R, et al. Targeting PDGFRα-activated glioblastoma through specific inhibition of SHP-2-mediated signaling. Neuro Oncol. 2019. PMID: 31232447. doi:10.1093/neuonc/noz107

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。